ClinicalTrials.gov
public full text
Public Domain
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma#806520
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia#1089036
- Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma#1295683
- Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma#1111467
- PRO#0118: Decitabine Plus Mini Flu-Bu#1075139
Record · ID 1183080
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive